Could CAR-T cells tame tough scleroderma in kids?

NCT ID NCT06792344

First seen Jan 05, 2026 · Last updated May 13, 2026 · Updated 21 times

Summary

This early-phase study tests a new treatment for children with severe systemic sclerosis (scleroderma) that hasn't responded to standard drugs. Doctors will give patients a single infusion of their own immune cells that have been reprogrammed to target and destroy faulty B cells. The main goal is to see if the treatment is safe and if it can improve skin stiffness and overall disease activity over six months.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS (SSC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Children's Hospital, Zhejiang University School of Medicine

    RECRUITING

    Hangzhou, Zhejiang, 0571, China

    Contact

  • Children's Hospital, Zhejiang University School of Medicine

    RECRUITING

    Hangzhou, Zhejiang, 310053, Christmas Island

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.